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Figure. Genetic variations in complement associated genes (HSCT recipient DNA). Figure shows a “heat map” of gene variants in recipients with and without TMA: each
column represents a gene,with heterozygous variants shaded light blue and homozygous variants shaded red. Each row is a single patient, illustrating thewide distribution
of variants in multiple genes in the TMA cases, while few variants are seen in the cases without TMA.
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Background: Transplant associated thrombotic micro-
angiopathy (TMA) is frequent after HSCT, and in severe cases
causes signiﬁcant morbidity and mortality. Currently there
are no data addressing individual susceptibility to transplant
associated TMA. Frequent genetic variants in ADAMTS13 and
complement genes have been described in other micro-
angiopathies such as aHUS and TTP. We hypothesized that
polymorphic variants in complement genes increase sus-
ceptibility to transplant associated TMA.
Methods: 90 consecutive allogeneic HSCT patients were
enrolledonaprospective TMAbiomarker studyand categorized
as having TMA or no TMA using rigorous diagnostic criteria
(Jodele et al, Blood 2014). Genomic DNAwas isolated from pre-
HSCT recipient blood. We used a candidate gene approach to
identify 12 geneswithin the complement pathway likely to play
a role in terminal complement activation, the likely effector
mechanism for vascular damage in TMA. All exons, ﬂanking
intronic and untranslated regions of ADAMTS13, CFH, CFI, CFB,
MCB, THBD, C3, C5, CFD, CFHR1, CFHR3 and CFHR5 were
sequenced using next generation sequencing technology. The
resulting sequence reads were aligned against the reference
DNA sequence and the variants were detected using NextGENesoftware. Observed variants were compared against dbSNP
(NCBI). Novel variants were further evaluated using laboratory
developed bioinformatic tools. Eight variants previously
described as likely pathogenic and 34 variants of unknown
pathogenic signiﬁcancewere identiﬁed. Resultswere compared
in patients with and without TMA.
Results: 77 patients had DNA available for analysis (34 with
TMA and 43 without TMA); 23 of 34 (68%) subjects with TMA
had complement gene variants as compared to 4 of 43 (9%)
controls without TMA (p<0.0001). Figure shows a “heat map”
of gene variants in recipients with and without TMA
illustrating the wide distribution of variants in multiple
genes in the TMA cases, while few variants are seen in those
without TMA. Likely pathogenic variants previously
described in other microangiopathies were seen in
ADAMTS13 (n¼2), CFH (n¼2), CFB (n¼1), CFHR5 (n¼1) and
CFI (n¼3), all in recipients with TMA. No known pathogenic
variants were seen in subjects without TMA. Two recipients
with TMA had homozygous deletion of CFHR3/R1, which was
not seen in the recipients without TMA. The median number
of gene variants (of known or unknown signiﬁcance) seen in
recipients with TMAwas 1 (0-7), and 0 (0-2) in those without
TMA (p<0.0001). Two subjects had 5 variants and one 7
variants and all three had fatal TMA.
Conclusion: The incidence of complement gene variants was
higher in patients with TMA as compared to patients without
TMA, indicating that genetic susceptibility importantly alters
risk. Additional larger studies are needed to deﬁne the
mechanistic importance of variants of unknown clinical
signiﬁcance.
97
High Hematopoietic Transplantation Comorbidity
Index Is Not Associated with Increased Transplant
Related Mortality: Review of a Large Cohort of
Pediatric Patients Undergoing Allogeneic Stem Cell
Transplantation Following Busulfan-Based Regimens
for Malignant and Non-Malignant Diseases
Justine Kahn 1, Naima Al Mulla 2, Mahvish Qureshi 1,
Grace Kim 1, Zhezhen Jin 3, Monica Bhatia 4, Esra Karamehmet 5,
Table 3
1yr TRM: HCT-CI Score Comparisons p-value
0 vs 1-2 0.180
1-2 vs3 0.238
3 0.706
Table 1
Grade and timing of aGVHD relative to absolute CD38 bright CD8+TEM cells/
mL prior to aGVHD onset
Patient Maximum
Absolute
CD38
Bright
CD8+ TEM
(cells/mL)
Maximum
Absolute
CD38
Bright
CD8+ TEM
(Day Post
HSCT)
Onset
of
acute
GVHD
(Day
Post
HSCT)
Onset of
CD38
Bright
CD8+ TEM
>35cells/
uL (Day
Post HSCT)
Maximum
grade of
aGVHD
Organ(s)
involved
1 64 26 33 26 1 Skin
2 69 48 58 37 3 GI
Liver
3 32 34 41 34 1 Skin
4 304 34 47 20 1 Skin
5 231 7 34 7 1 Skin
6 41 24 34 24 2 Skin
7 99 25 32 25 4 Skin
Liver
8 98 16 23 16 3 Skin
GI
9 90 52 69 17 3 Skin
Liver
10 183 37 52 20 3 Skin
GI
Liver
11 42 33 42 33 3 Skin
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Introduction: Identiﬁcation of patients at high risk for trans-
plant relatedmortality (TRM)prior to allogeneichematopoietic
cell transplantation (alloHCT) is crucial. However, the hetero-
geneity of alloHCT indications, conditioning regimens, patient
characteristics and center-speciﬁc practices makes deﬁning
generalizable risk factors for TRM a perpetual challenge. In a
retrospective study, Smith et al. (Blood, 2011) concluded that
Sorror’s 17-item pre-alloHCTadult comorbidity indexwas also
an effective tool for risk-stratifying pediatric alloHCT patients.
In this study,weattempt to re-validate theHCT-CIpublishedby
Smith et al. in a cohort of patients receiving well-deﬁned
Busulfan (Bu)-based conditioning regimens.
Methods: Retrospective cohort study of 165 patients (<22y)
who underwent alloHCT. Patients conditioned with 1 of 3
Bu-based regimens were included: reduced intensity (RIC):
Bu (6.4-8mg/kg)+ Fludarabine (Flu) (150mg/m2), reduced
toxicity (RTC): Bu (12.8-16mg/kg)+ Flu (180mg/m2) and
myeloablative (MAC): Bu (12.8-16mg/kg)+ cyclophospha-
mide (120-200mg/kg) or melphalan (135mg/m2).
Results: Median age at alloHCT was 9.5y (0.1-22y), malig-
nant group n¼102, non-malignant group n¼63. Pre-alloHCT
comorbidities were scored using HCT-CI and risk group
numbers were as follows: 32 (19.4%) group 0, 69 (41.8%)
group 1-2, 64 (38.8%) group 3. The difference in incidence
of TRM at 1y in each HCT-CI group was not statistically sig-
niﬁcant for malignant vs non-malignant patients. 1yr TRM of
patients receiving RIC, RTC and MAC regimens was also not
signiﬁcantly impacted by pre-transplant HCT-CI scores in
each of these cohorts. Data outlined in supplemental tables.
Conclusion: Preliminary results suggest that the HCT-CI as it
standsmay not be a generalizable risk stratiﬁcation tool for all
pediatric alloHCT patients. Contrary to aforementioned
studies, we were unable to demonstrate poorer outcomes in
patientswithHCT-CI score3. One potential reason could be a
smaller sample size in our study (n¼166 vs. 252).We excluded
total body irradiation as it is only used inMAC regimens at our
center which might have skewed the comparison between
RIC/RTC vs. MAC thus making ﬁndings generalizable. FurtherTable 1
HCT-CI
Score
1y TRM All Patients p-value
Number Deceased Living
0 32 9 (28.1%) 23 (71.9%) 0.299
1-2 69 19 (27.5%) 50 (72.5%)
3 64 11 (17.2%) 53 (82.8%)
All 165 39 (23.6%) 126 (76.4%)
Table 2
HCT-CI
Score
1y TRM: Conditioning Regimens p-value
RIC RTC MAC
0 16.7% (1/6) 0% (0/11) 20% (3/15) 0.376
1-2 5% (1/20) 13% (3/23) 15.4% (4/26) 0.576
3 0% (0/18) 10.7% (3/28) 11.1% (2/18) 0.576analysis is currently being conducted to identify risk factors
distinct fromtheHCT-CI thatmayhave ahigher impactonTRM
in pediatric patients undergoing alloHCT.98
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Acute graft versus host disease (aGVHD) is an important
complication of allogeneic hematopoietic stem cell trans-
plantation (HSCT). A need exists for validated biomarkersGI
12 36 11 15 11 4 Skin
GI
13 82 15 29 15 4 GI
14 37 43 44 12 2 Skin
15 151 45 79 15 3 Skin
GI
16 63 23 33 23 4 Skin
GI
17 47 25 31 25 1 Skin
18 87 17 18 17 3 GI
19 69 56 59 56 1 Skin
20 2 25 28 NA 1 Skin
21 12 36 37 NA 1 Skin
22 70 28 38 21 1 Skin
23 128 42 45 28 3 Skin
GI
